Eton Pharmaceuticals Free Cash Flow (FCF) History (ETON)
Eton Pharmaceuticals reported $10.2M in free cash flow for fiscal 2025, an increase of 980.70% from the previous fiscal year, with a free cash flow margin of 12.75%.
View full Eton Pharmaceuticals company overviewEton Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.2M | $9.2M | +980.70% | +12.75% |
| 2024 | 2024-12-31 | $943,000 | −$5.9M | −86.16% | +2.42% |
| 2023 | 2023-12-31 | $6.8M | $2.0M | +42.48% | +21.54% |
| 2022 | 2022-12-31 | $4.8M | $9.5M | — | +22.51% |
| 2021 | 2021-12-31 | −$4.7M | $17.7M | — | −21.67% |
| 2020 | 2020-12-31 | −$22.4M | −$3.3M | — | −57425.64% |
| 2019 | 2019-12-31 | −$19.1M | −$10.7M | — | −1993.95% |
| 2018 | 2018-12-31 | −$8.4M | — | — | — |
Eton Pharmaceuticals quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.3M | −$709,000 | −8.91% | +19.29% |
| Q1 2026 | 2026-03-31 | $7.3M | $5.2M | +250.72% | +30.21% |
| Q4 2025 | 2025-12-31 | −$11.6M | −$10.8M | — | −54.51% |
| Q3 2025 | 2025-09-30 | $11.7M | $8.8M | +297.76% | +52.28% |
| Q2 2025 | 2025-06-30 | $8.0M | $6.7M | +534.18% | +42.05% |
| Q1 2025 | 2025-03-31 | $2.1M | $4.6M | — | +12.09% |
| Q4 2024 | 2024-12-31 | −$777,000 | −$1.2M | — | −6.67% |
| Q3 2024 | 2024-09-30 | $3.0M | $2.1M | +238.14% | +28.59% |
| Q2 2024 | 2024-06-30 | $1.3M | −$5.8M | −82.33% | +13.83% |
| Q1 2024 | 2024-03-31 | −$2.5M | −$939,000 | — | −31.22% |
| Q4 2023 | 2023-12-31 | $387,000 | −$2.4M | −86.32% | +5.29% |
| Q3 2023 | 2023-09-30 | $873,000 | $2.6M | — | +12.42% |
| Q2 2023 | 2023-06-30 | $7.1M | $4.7M | +189.92% | +59.21% |
| Q1 2023 | 2023-03-31 | −$1.5M | −$2.8M | — | −29.19% |
| Q4 2022 | 2022-12-31 | $2.8M | $5.8M | — | +33.28% |
| Q3 2022 | 2022-09-30 | −$1.7M | $5.5M | — | −52.90% |
| Q2 2022 | 2022-06-30 | $2.5M | $7.5M | — | +33.30% |
| Q1 2022 | 2022-03-31 | $1.2M | $4.1M | — | +55.51% |
| Q3 2021 | 2021-09-30 | −$3.0M | $4.3M | — | −380.90% |
| Q4 2020 | 2020-12-31 | −$7.2M | −$3.3M | — | −8920.99% |
| Q3 2020 | 2020-09-30 | −$5.1M | −$1.8M | — | — |
| Q2 2020 | 2020-06-30 | −$2.9M | $2.0M | — | −14265.00% |
| Q1 2020 | 2020-03-31 | −$7.2M | −$66,000 | — | −7293.94% |
| Q4 2019 | 2019-12-31 | −$3.9M | −$2.1M | — | −845.75% |
| Q3 2019 | 2019-09-30 | −$3.2M | −$904,000 | — | — |
| Q2 2019 | 2019-06-30 | −$4.8M | −$2.6M | — | — |
| Q1 2019 | 2019-03-31 | −$7.2M | −$5.2M | — | −1431.00% |
| Q4 2018 | 2018-12-31 | −$1.8M | — | — | — |
| Q3 2018 | 2018-09-30 | −$2.3M | — | — | — |
| Q2 2018 | 2018-06-30 | −$2.3M | — | — | — |
| Q1 2018 | 2018-03-31 | −$1.9M | — | — | — |
Eton Pharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$22.4M to $10.2M, a net increase of $32.6M. Eton Pharmaceuticals's latest reported quarter, Q2 2026, generated $7.3M in free cash flow, a decrease of 8.91% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Eton Pharmaceuticals filings at SEC.gov ↗